Sequenom's Q2 Revenues Rise 17 Percent as It Names T21 Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its second-quarter revenues jumped 17 percent as sales rose for its genetic analysis products and diagnostic services.

The San Diego-based molecular diagnostics developer brought in total revenues of $13.3 million for the three months ended June 30, compared to revenues of $11.4 million for the second quarter of 2010. It missed Wall Street's estimate of $13.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.